Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

The blood pressure-elevating effect of Red Bull energy drink is mimicked by caffeine but through different hemodynamic pathways.

Authors:
Jennifer L Miles-Chan Nathalie Charrière Erik K Grasser Jean-Pierre Montani Abdul G Dulloo

Physiol Rep 2015 Feb 25;3(2). Epub 2015 Feb 25.

Laboratory of Integrative Cardiovascular and Metabolic Physiology, Division of Physiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland.

The energy drink Red Bull (RB) has recently been shown to elevate resting blood pressure (BP) and double product (reflecting increased myocardial load). However, the extent to which these effects can be explained by the drink's caffeine and sugar content remains to be determined. We compared the cardiovascular impact of RB to those of a comparable amount of caffeine, and its sugar-free version in eight young healthy men. Participants attended four experimental sessions on separate days according to a placebo-controlled randomized crossover study design. Beat-to-beat hemodynamic measurements were made continuously for 30 min at baseline and for 2 h following ingestion of 355 mL of either (1) RB + placebo; (2) sugar-free RB + placebo; (3) water + 120 mg caffeine, or (4) water + placebo. RB, sugar-free RB, and water + caffeine increased BP equally (3-4 mmHg) in comparison to water + placebo (P < 0.001). RB increased heart rate, stroke volume, cardiac output, double product, and cardiac contractility, but decreased total peripheral resistance (TPR) (all P < 0.01), with no such changes observed following the other interventions. Conversely, sugar-free RB and water + caffeine both increased TPR in comparison to the water + placebo control (P < 0.05). While the impact of RB on BP is the same as that of a comparable quantity of caffeine, the increase occurs through different hemodynamic pathways with RB's effects primarily on cardiac parameters, while caffeine elicits primarily vascular effects. Additionally, the auxiliary components of RB (taurine, glucuronolactone, and B-group vitamins) do not appear to influence these pathways.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393199PMC
http://dx.doi.org/10.14814/phy2.12290DOI Listing
February 2015

Publication Analysis

Top Keywords

water placebo
12
sugar-free water
8
impact comparable
8
water caffeine
8
double product
8
red bull
8
caffeine increased
8
placebo sugar-free
8
energy drink
8
comparison water
8
caffeine
8
hemodynamic pathways
8
water
6
placebo
5
increased equally
4
influence pathways
4
equally 3-4
4
3-4 mmhg
4
placebo 0001
4
0001 increased
4

Keyword Occurance

Similar Publications

Re-WRAP (Remyelination for women at risk of axonal loss and progression): A phase II randomized placebo-controlled delayed-start trial of Bazedoxifene for myelin repair in multiple sclerosis.

Authors:
Alyssa Nylander Annika Anderson William Rowles Stephanie Hsu Ann A Lazar Sonia R Mayoral Sarah E Pease-Raissi Ari Green Riley Bove

Contemp Clin Trials 2023 Sep 20;134:107333. Epub 2023 Sep 20.

University of California San Francisco, Weill Institute for Neurosciences, UCSF, San Francisco, CA, USA. Electronic address:

Introduction: Multiple sclerosis (MS) is a major cause of disability in young and middle-aged people, and myelin repair therapies are needed to slow or potentially reverse this damage. Bazedoxifene (BZA) is a selective estrogen receptor modulator identified in a novel high-throughput unbiased screen for its remyelinating potential, and its remyelinating effects were demonstrated in pre-clinical models.

Methods: This is a single-center, double blind, randomized, controlled, delayed-start Phase 2 clinical trial (NCT04002934) investigating the remyelinating effects of BZA relative to placebo. Read More

View Article and Full-Text PDF
September 2023
Similar Publications

Risk of COVID-19 after natural infection or vaccination.

Authors:
Anne-Marie Rick Matthew B Laurens Ying Huang Chenchen Yu Thomas C S Martin Carina A Rodriguez Christina A Rostad Rebone M Maboa Lindsey R Baden Hana M El Sahly Beatriz Grinsztejn Glenda E Gray Cynthia L Gay Peter B Gilbert Holly E Janes James G Kublin Yunda Huang Brett Leav Ian Hirsch Frank Struyf Lisa M Dunkle Kathleen M Neuzil Lawrence Corey Paul A Goepfert Stephen R Walsh Dean Follmann Karen L Kotloff

EBioMedicine 2023 Sep 20;96:104799. Epub 2023 Sep 20.

Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Read More

View Article and Full-Text PDF
September 2023
Similar Publications

Vitamin B12 effectiveness in the management of hospitalized COVID-19 and its clinical outcomes and complications: A randomized clinical trial.

Authors:
Zahra Erfani Nafiseh Alizadeh Neda Faraji Alireza Teymouri

Health Sci Rep 2023 Sep 14;6(9):e1509. Epub 2023 Sep 14.

School of Medicine Tehran University of Medical Sciences Tehran Iran.

Background And Aims: Since 2019, severe acute respiratory syndrome coronavirus 2, has spread and challenged the health care system for treatment which is mainly limited to supportive care. It is well-established that malnutrition impedes the immunity in human bodies, and makes it vulnerable to microorganisms. Vitamin B12 is one of the agents that has critical roles in body systems. Read More

View Article and Full-Text PDF
September 2023
Similar Publications

Peroral Exposure to Ethanol Extract Caused Neuronal Degeneration and Astrogliosis in Wistar Rats' Prefrontal Cortex.

Authors:
Olatunji Sunday Yinka Ogunnaike Philip Olubunmi Abijo Ayodeji Zabdiel Owolabi Joshua Oladele Adelodun Stephen Taiye Adeoye Ayodele Fasesan Oluwatoyin Adetutu Olanrewaju John Afees Adegbite Ademola Kayode

Ann Neurosci 2023 Apr 19;30(2):84-95. Epub 2022 Oct 19.

Department of Anatomy, School of Basic Medical Sciences, Benjamin Carson (Snr.) College of Medical and Health Sciences, Ilishan-Remo, Ogun State Nigeria.

Background: Despite widespread concerns about its possible side effects, notably on the prefrontal cortex (PFC), which mediates cognitive processes, the use of as a medicinal and recreational drug is expanding exponentially. This study evaluated possible behavioral alterations, neurotransmitter levels, histological, and immunohistochemical changes in the PFC of Wistar rats exposed to .

Purpose: To evaluate the effect of graded doses of on the PFC using behavioural, histological, and immunohistochemical approaches. Read More

View Article and Full-Text PDF
April 2023
Similar Publications

Tranexamic acid in a mouse model of cerebral amyloid angiopathy: setting the stage for a novel stroke treatment approach.

Authors:
Zikou Liu Fiona M McCutcheon Heidi Ho Joanne Chia Yunxin Xiao Isabel Tippett Charithani B Keragala Geoffrey C Cloud Robert L Medcalf

Res Pract Thromb Haemost 2023 Aug 9;7(6):102166. Epub 2023 Aug 9.

Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.

Background: Symptomatic intracerebral hemorrhage (sICH) commonly occurs in patients with cerebral amyloid angiopathy (CAA). Amyloid also initiates plasminogen activation and might promote sICH.

Objectives: As amyloid-driven plasmin formation can be blocked by tranexamic acid (TXA), we aimed to evaluate the biodistribution and long-term consequences of TXA on brain amyloid-beta (Aβ) levels, inflammation, and neurologic function in APP/PS1 mice. Read More

View Article and Full-Text PDF
August 2023
Similar Publications
}
© 2023 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap